4D Molecular Therapeutics, Inc.
FDMT
$14.22
-$0.41-2.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 278,712.12% | 383,560.87% | 230,194.59% | 605.88% | -99.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 278,712.12% | 383,560.87% | 230,194.59% | 605.88% | -99.84% |
| Cost of Revenue | 39.82% | 41.23% | 36.87% | 44.05% | 53.60% |
| Gross Profit | 14.21% | 16.01% | 23.42% | -43.98% | -87.83% |
| SG&A Expenses | -2.64% | -2.86% | 5.33% | 11.72% | 23.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.16% | 30.56% | 29.05% | 35.58% | 45.51% |
| Operating Income | 11.58% | 12.83% | 16.29% | -35.52% | -67.91% |
| Income Before Tax | 8.65% | 8.81% | 12.90% | -45.79% | -78.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.65% | 8.81% | 12.90% | -45.79% | -78.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.65% | 8.81% | 12.90% | -45.79% | -78.49% |
| EBIT | 11.58% | 12.83% | 16.29% | -35.52% | -67.91% |
| EBITDA | 12.06% | 13.31% | 16.72% | -36.58% | -70.27% |
| EPS Basic | 21.64% | 15.04% | 14.27% | -32.19% | -53.99% |
| Normalized Basic EPS | 22.80% | 16.32% | 15.64% | -30.81% | -53.98% |
| EPS Diluted | 21.64% | 15.04% | 14.27% | -32.19% | -53.99% |
| Normalized Diluted EPS | 22.80% | 16.32% | 15.64% | -30.81% | -53.98% |
| Average Basic Shares Outstanding | 15.94% | 9.82% | 7.40% | 10.08% | 17.50% |
| Average Diluted Shares Outstanding | 15.94% | 9.82% | 7.40% | 10.08% | 17.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |